TM4SF1 is a promising target because its expression is not limited to HV bladder cancers and its negative association with PVRL4/PRR4 expression suggests that targeted therapy against TM4SF1 could complement existing targeted agents. Here, PRR4 is linked to urinary bladder cancer.